Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical

P. K. Coyle

doi:10.1007/s13311-023-01431-y

Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical

P. K. Coyle

Neurology

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	1692-1693
Number of pages	2
Journal	Neurotherapeutics
Volume	20
Issue number	6
DOIs	https://doi.org/10.1007/s13311-023-01431-y
State	Published - Oct 2023

Keywords

Ocrelizumab
Primary progressive MS
Real world data

Access to Document

10.1007/s13311-023-01431-y

Cite this

@article{becf2e3caef24f68bd66401d9c5e40a2,

title = "Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical",

keywords = "Ocrelizumab, Primary progressive MS, Real world data",

author = "Coyle, \{P. K.\}",

year = "2023",

month = oct,

doi = "10.1007/s13311-023-01431-y",

language = "English",

volume = "20",

pages = "1692--1693",

journal = "Neurotherapeutics",

issn = "1933-7213",

number = "6",

}

TY - JOUR

T1 - Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical

AU - Coyle, P. K.

PY - 2023/10

Y1 - 2023/10

KW - Ocrelizumab

KW - Primary progressive MS

KW - Real world data

UR - https://www.scopus.com/pages/publications/85173492928

U2 - 10.1007/s13311-023-01431-y

DO - 10.1007/s13311-023-01431-y

M3 - Comment/debate

C2 - 37794276

AN - SCOPUS:85173492928

SN - 1933-7213

VL - 20

SP - 1692

EP - 1693

JO - Neurotherapeutics

JF - Neurotherapeutics

IS - 6

ER -

Should Age 65 be a cutoff for Primary Progressive Multiple Sclerosis therapy? Real World Data is Critical

Keywords

Access to Document

Other files and links

Fingerprint

Cite this